TLR9 and infection: The use of CPG as an adjuvant in vaccines is a strategy widely used against some models of infection, as it has great potential to induce and increase Th1 type immune response through TLR9 activation (Klinman et al., 2004; Latz et al., 2004; Krieg, 2006).